Peters, K., Affronti, M. L., Woodring, S., Lipp, E., Healy, P., McShwrry, F., … Friedman, H. (n.d.). QOL-20. Low-dose Naltrexone in newly diagnosed high-grade glioma: placebo-controlled, double-blind, randomized pilot study. In Neuro-Oncology (Vol. 17, pp. v192–v192). San Antoni, TX: Oxford University Press (OUP). https://doi.org/10.1093/neuonc/nov230.20

Peters, Katherine, Mary L. Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, Frances McShwrry, James Herndon, et al. “QOL-20. Low-dose Naltrexone in newly diagnosed high-grade glioma: placebo-controlled, double-blind, randomized pilot study.” In Neuro-Oncology, 17:v192–v192. Oxford University Press (OUP), n.d. https://doi.org/10.1093/neuonc/nov230.20.

Peters K, Affronti ML, Woodring S, Lipp E, Healy P, McShwrry F, et al. QOL-20. Low-dose Naltrexone in newly diagnosed high-grade glioma: placebo-controlled, double-blind, randomized pilot study. In: Neuro-Oncology. Oxford University Press (OUP); p. v192–v192.

Peters, Katherine, et al. “QOL-20. Low-dose Naltrexone in newly diagnosed high-grade glioma: placebo-controlled, double-blind, randomized pilot study.” Neuro-Oncology, vol. 17, no. Suppl 5, Oxford University Press (OUP), pp. v192–v192. Manual, doi:10.1093/neuonc/nov230.20.

Peters K, Affronti ML, Woodring S, Lipp E, Healy P, McShwrry F, Herndon J, Flahiff C, Miller E, Freeman M, Minchew J, Zalutsky B, Taylor B, Boulton S, Randazzo D, Desjardins A, Vlahovic G, Bigner D, Friedman H. QOL-20. Low-dose Naltrexone in newly diagnosed high-grade glioma: placebo-controlled, double-blind, randomized pilot study. Neuro-Oncology. Oxford University Press (OUP); p. v192–v192.